Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dendreon Corporation
Yumanity goes public by merging with Proteostasis; it is accelerating its Parkinson’s program because of mouse model data showing disease-modifying potential. Proteostasis will out-license its CF assets.
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Next-generation CFTR corrector elexacaftor aims to be first cystic fibrosis product with minimal function mutations claim after winning out over VX-659 thanks to tolerability advantage in dueling Phase III programs testing combination with the components of Vertex’ Symdeko.
The UK’s Competition and Markets Authority has issued a statement of objections to Advanz, Morningside and wholesaler Alliance Healthcare after provisionally finding that the firms broke competition law by arranging to carve up the UK market for nitrofurantoin.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries